PD-L1 expression and CD8-positive tumor-infiltrating lymphocyte (CD8+ TIL) infiltration within the tumor microenvironment have been reported to be the two most promising predictors of treatment response to anti-PD1/PD-L1 immunotherapy and overall prognosis8–12. The gene discussed is CD274; the disease is neoplasm.